The oral toxicity test in mice using medical device extracts is a fundamental component of biological safety evaluation under ISO 10993 and GB/T 16886 standards, designed to detect acute systemic toxicity from leachable substances released by device materials. This article provides a comprehensive technical overview of the test principle, sample preparation, extraction procedures, animal test methodology, and regulatory applications. It serves as a practical reference for manufacturers, regulatory affairs professionals, and laboratory scientists involved in medical device biocompatibility assessment and market registration.
Technical Overview
The oral toxicity test in mice using medical device extracts is an in vivo acute systemic toxicity screening test performed as part of the biological evaluation of medical devices. The test evaluates whether extractable and leachable substances released from device materials, biomaterials, coatings, or packaging components can induce adverse systemic effects following a single oral exposure. It is conducted in accordance with the test methods described in ISO 10993-11 (Tests for systemic toxicity) and GB/T 16886.11, with sample preparation performed per ISO 10993-12 and GB/T 16886.12.
The test principle is straightforward: test articles are extracted under standardized, exaggerated conditions in both polar and non-polar vehicles, and the resulting extracts are administered to mice by oral gavage at a defined dose volume. Animals are then observed for 14 days for mortality, clinical signs of toxicity, body weight changes, and gross pathological findings, with results compared against concurrent vehicle control groups. The oral route is particularly relevant for devices that contact the gastrointestinal tract, mucosal membranes, or the oral cavity, and it also serves as a general screening route for systemic toxicity in many biological evaluation programs.
This test is typically required within the biological evaluation framework of ISO 10993-1 for devices with contact durations exceeding 24 hours, for externally communicating devices, and for implantable devices. Study data generated in compliance with Good Laboratory Practice (GLP) principles by accredited third-party laboratories are widely accepted in support of regulatory submissions to authorities such as the NMPA, the U.S. FDA, and notified bodies under the EU Medical Device Regulation (MDR).
Testing Samples
A wide range of medical devices and materials can be evaluated using this method. Typical sample categories submitted for testing include the following:
Sterile Single-Use and Fluid-Path Devices
Syringes, infusion sets, blood transfusion sets, catheters, cannulae, filters, and tubing sets are frequently tested because fluid-path materials may release extractables directly into infused liquids that are ultimately administered to patients.
Implantable Devices and Biomaterials
Orthopedic implants, dental materials, absorbable polymers, surgical meshes, bone cements, wound dressings, and tissue-engineering scaffolds are evaluated because long-term or permanent tissue contact increases the cumulative exposure risk from leachable substances.
Devices Contacting Mucosal Membranes and the Digestive Tract
Gastrointestinal tubes, endoscopic accessories, oral care products, dentures, and respiratory devices with gas-pathway contact are commonly assessed, as the oral exposure route directly simulates the clinical exposure scenario for these products.
Raw Materials, Coatings, and Process Chemicals
Polymer resins, curing agents, adhesives, colorants, surface coatings, sterilization residuals, and packaging materials may be screened during material selection and design verification, before device-level testing is performed.
Modified or Changed Products
Devices that have undergone material substitution, manufacturing process changes, sterilization method changes, or supplier changes often require re-evaluation to confirm that the toxicological profile remains acceptable under change-control procedures.
Testing Items
The core testing items and endpoints of the study include:
- Acute oral systemic toxicity of polar extracts (e.g., 0.9% sodium chloride solution)
- Acute oral systemic toxicity of non-polar extracts (e.g., sesame oil or cottonseed oil)
- Mortality and survival observation over a 14-day post-dose period
- Clinical observation of toxic signs, including posture, activity, fur condition, respiration, salivation, tremors, convulsions, and central nervous system effects
- Body weight measurement before dosing and at defined intervals (commonly days 0, 7, and 14)
- Gross necropsy examination of major organs at study termination
- Estimation of the maximum tolerated dose (MTD) or qualitative determination of no observed adverse effect under test conditions
- Comparison of treatment groups against concurrent vehicle control groups for result interpretation
Testing Methods
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12 and GB/T 16886.12. Test articles are cut, cleaned, and sterilized as appropriate to their intended clinical use. Extraction is performed in both a polar vehicle (sterile 0.9% sodium chloride solution or water for injection) and a non-polar vehicle (a vegetable oil such as sesame oil or cottonseed oil) to cover the polarity range of potential leachables. Standard extraction ratios based on device geometry include:
- For materials with a thickness below 0.5 mm: 6 cm² of surface area per milliliter of extraction vehicle
- For materials with a thickness of 0.5 mm to 1.0 mm: 3 cm² per milliliter
- For materials thicker than 1.0 mm: 1.25 cm² per milliliter
- For irregular solids where surface area cannot be determined: a mass-based ratio, commonly 0.1 g to 0.2 g of material per milliliter of vehicle
Extraction is conducted under one of the standard condition sets, most commonly 37 °C ± 1 °C for 24 hours ± 2 hours, with alternative conditions of 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour selected when justified by material properties and clinical use conditions. Extracts are used promptly after preparation to prevent degradation or compositional change.
Test System
Healthy adult mice, typically of a common laboratory strain such as BALB/c, ICR, or KM mice, are used. Animals generally weigh between 18 g and 22 g at study initiation, with both sexes represented, commonly five males and five females per group. Minimum group sizes of three animals per sex may be applied for screening purposes when scientifically justified. Animals are acclimatized for at least 5 to 7 days before dosing and housed under controlled environmental conditions with ad libitum access to food and water. All procedures are reviewed and approved by an institutional animal care committee in accordance with animal welfare legislation and the 3R principles of replacement, reduction, and refinement.
Dose Administration
Each extract is administered as a single dose by oral gavage at a standard dose volume of 50 mL per kilogram of body weight. Corresponding vehicle control groups receive the neat extraction vehicle at the same dose volume. For a 20 g mouse, this corresponds to a 1.0 mL dose. Animals may be fasted briefly before dosing depending on the study protocol, and dosing is performed with the extract maintained at a consistent temperature.
Observation and Evaluation
Clinical observations are performed frequently on the day of dosing, with particular attention during the first several hours after administration, and at least once daily thereafter for 14 consecutive days. Observed parameters include mortality, general behavior, neurological signs, respiratory effects, and dermatological changes. Body weights are recorded before dosing and periodically thereafter, typically weekly. At the end of the observation period, surviving animals are humanely euthanized and subjected to gross necropsy. The study is considered valid when vehicle control animals remain normal; significant toxic reactions, mortality, or body weight suppression exceeding approximately 10% to 15% in extract-treated animals indicate a positive systemic toxicity response requiring further toxicological assessment.
Applications
The oral toxicity test with medical device extracts supports a broad range of regulatory and product development objectives:
- Preparation of biological evaluation reports required for medical device registration with the NMPA, U.S. FDA submissions such as 510(k) and PMA, CE marking under the EU MDR, and submissions in other jurisdictions
- Generation of GLP-compliant study data forming part of the overall toxicological risk assessment for leachables and extractables
- Material selection and comparative screening during research and development of new polymers, coatings, and formulations
- Verification and change control following modification of materials, manufacturing processes, sterilization methods, or suppliers
- Support of biological safety documentation for custom-made devices and small-series manufacturers
- Complementary evidence alongside cytotoxicity, sensitization, irritation, genotoxicity, and implantation tests within a complete ISO 10993-1 evaluation program
FAQ
When is the mouse oral toxicity test with extracts required?
It is generally required when a biological evaluation under ISO 10993-1 identifies acute systemic toxicity as a relevant endpoint, typically for surface-contacting devices with contact exceeding 24 hours, externally communicating devices, implantable devices, and any device where the oral or gastrointestinal exposure route is clinically relevant.
Why must both polar and non-polar extraction vehicles be used?
Leachable substances cover a wide range of chemical polarities. Polar vehicles such as saline extract water-soluble substances, while non-polar vehicles such as vegetable oils extract lipophilic substances. Testing both extract types ensures that the toxicological screening covers the full spectrum of potentially migratable compounds.
What extraction conditions are most commonly selected?
The condition of 37 °C ± 1 °C for 24 hours ± 2 hours is the most widely used because it is mild, broadly applicable, and closely aligned with physiological exposure. Higher-temperature conditions may be selected to achieve exaggerated extraction when justified by the material and its intended use.
How long does the study take to complete?
Including sample preparation, extraction, a 14-day observation period, necropsy, and report issuance, a typical study is completed within approximately four to six weeks, depending on laboratory scheduling and protocol complexity.
What constitutes a passing result?
A test is considered negative when no mortality occurs and no treatment-related clinical signs, body weight losses, or gross pathological findings are observed in the extract-treated groups relative to the corresponding vehicle controls. A negative result supports the conclusion that the device extract does not present acute oral systemic toxicity under the conditions of the test.
Can in vitro testing replace this animal test?
In vitro methods such as cytotoxicity testing per ISO 10993-5 are valuable screening tools but cannot yet fully replicate systemic toxicokinetics and whole-organism responses. In accordance with the 3R principles, in vivo testing is applied only when justified by the risk assessment, with animal numbers minimized and study design refined to reduce distress wherever possible.